Omixon Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
61
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$25M
Omixon General Information
Description
Developer of genetics and molecular diagnostic products intended to be used in transplantation. The company provides laboratory reagents and software to determine human leukocyte antigen (HLA) genotypes based on next-generation sequencing and also provides post-transplant monitoring, enabling clinical labs with diagnostic products to improve patient outcomes.
Contact Information
Website
www.omixon.comCorporate Office
- Kaposvár utca 14-18.
- Budapest, 1117
- Hungary
Corporate Office
- Kaposvár utca 14-18.
- Budapest, 1117
- Hungary
Omixon Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 16-Oct-2024 | $25M | Completed | Generating Revenue | ||
| 6. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 5. Later Stage VC | 15-Dec-2016 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 17-Nov-2015 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 14-May-2014 | Completed | Generating Revenue | |||
| 2. Grant | 09-May-2014 | $450.12 | $1.73M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 31-May-2012 | $1.73M | $1.73M | Completed | Startup |
Omixon Comparisons
Industry
Financing
Details
Omixon Competitors (16)
One of Omixon’s 16 competitors is RareCyte, a Venture Capital-Backed company based in Seattle, WA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| RareCyte | Venture Capital-Backed | Seattle, WA | ||||
| MC Diagnostics | Corporate Backed or Acquired | Bromborough, United Kingdom | ||||
| Devyser Diagnostics | Formerly PE-Backed | Arsta, Sweden | ||||
| Lunaphore | Formerly VC-backed | Tolochenaz, Switzerland | ||||
| Biocartis | Venture Capital-Backed | Mechelen, Belgium |
Omixon Signals
Omixon Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Euroventures | Venture Capital | Minority | ||
| FastVentures | Venture Capital | Minority | ||
| Futuremed Health Care Products | Corporation | Minority |
Omixon FAQs
-
When was Omixon founded?
Omixon was founded in 2011.
-
Where is Omixon headquartered?
Omixon is headquartered in Budapest, Hungary.
-
What is the size of Omixon?
Omixon has 61 total employees.
-
What industry is Omixon in?
Omixon’s primary industry is Diagnostic Equipment.
-
Is Omixon a private or public company?
Omixon is a Private company.
-
What is the current valuation of Omixon?
The current valuation of Omixon is .
-
What is Omixon’s current revenue?
The current revenue for Omixon is .
-
How much funding has Omixon raised over time?
Omixon has raised $6.91M.
-
Who are Omixon’s investors?
, , Euroventures, FastVentures, and Futuremed Health Care Products are 5 of 10 investors who have invested in Omixon.
-
Who are Omixon’s competitors?
RareCyte, MC Diagnostics, Devyser Diagnostics, Lunaphore, and Biocartis are some of the 16 competitors of Omixon.
-
When was Omixon acquired?
Omixon was acquired on 16-Oct-2024.
-
Who acquired Omixon?
Omixon was acquired by Werfen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process